In August ----, the Minister of Public Health and Dutch centre for stem cell donors, Matchis, launched a campaign to recruit new stem cell donors, addressing the Netherlands current shortage for the treatment of leukaemia and other blood cancers. Data published in the European Heart Journal in August ----, revealed that cardiovascular disease in -- European countries (including the Netherlands) now accounts for far fewer deaths than cancer in men, owing to improvements in prevention and treatments. ...In August ----, the Minister of Public Health and Dutch centre for stem cell donors, Matchis, launched a campaign to recruit new stem cell donors, addressing the Netherlands current shortage for the treatment of leukaemia and other blood cancers. Data published in the European Heart Journal in August ----, revealed that cardiovascular disease in -- European countries (including the Netherlands) now accounts for far fewer deaths than cancer in men, owing to improvements in prevention and treatments. In July ----, Zambon and its partner Newron Pharmaceuticals launched Xadago (safinamide) in the Netherlands for the treatment of mid- to late-stage Parkinson s disease. In June ----, the Dutch minister of health proposed a change in the current abortion legislation, by limiting the period of time in which doctors can carry out the medical procedure. Mylan achieved total revenues in Q---, ended June --, worth USD-,---.-mn, up by -.- over the
...Government cost-cutting measures will continue to depress pricing margins, particularly in the generic drug market. Tightening operating environment to threaten the country s already small number of multinational manufacturing plants. ...Difficulties and delays in getting reimbursement for expensive novel treatments, with the no cure, no pay being the latest measure to target patented drugs. Low rate of economic growth in the short-term could negatively affect the development of the pharmaceuticals market and the over-the-counter segment in particular. The government s social insurance reform is likely to cap growth, while insurers continue to include cheaper generic medicines under their preference policies. ...Low rate of economic growth in the short-term could negatively affect the development of the pharmaceuticals market and the over-the-counter segment in particular. The government s social insurance reform is likely to cap growth, while insurers continue to include cheaper generic medicines under their preference policies.
...Government cost-cutting initiatives, which have tightened criteria for the reimbursement system. Drastic price cuts and agreements not to raise branded drug prices have reduced the market s value in the past. ...
